Disrupting organ transplantation with unlimited, whole, AI-guided, human livers

The Khufu or Giza Pyramid in Egypt, built in ancient times, is the largest man-made pyramid, while the liver is the largest internal organ in the human body. This aspect of mass or size is a key component of therapy and is a major therapeutic challenge; incidentally, ability to achieve liver mass is one key aspect of Khufu's competitive advantage.

Khufu Therapeutics employs in vitro/in vivo manufacturing and tissue perfusion to grow personalized or allogeneic full-scale livers in just two months.

Founder Dr. Natesh Parashurama, MD PhD, is an MIT, Harvard, Stanford, and UCSF trained surgeon and bioengineer, former tenure track professor, who spent over 15 years in liver regenerative medicine uncovering novel mechanisms of liver growth, liver maturation, and the transition from growth to maturation.

Khufu's propietary platform integrates synthetic biology, organ engineering, and AI-driven computational modeling to build liver tissue rapidly and accurately.

There is no limit to the number of livers Khufu can grow. This will disrupt organ transplantation, starting from harvest stage to the transplant stage, rounding out the true need for new livers.

Khufu is revolutionizing how the world approaches organ failure, starting with the liver.

ABOUT

THE PROBLEM

Cirrhosis is a global epidemic hiding in plain sight.

Over 4 million Americans and 100 million people worldwide are living with end-stage liver disease, yet fewer than 0.25% receive a transplant each year. Every other patient is left to manage symptoms while their liver slowly fails.

Unlike other organs, the failing liver cannot be replaced by machines or treated with drugs. As fibrosis progresses to cirrhosis, the organ’s architecture collapses—hepatocytes die, scar tissue replaces healthy tissue, and function disappears.

For 20 years, major pharmaceutical and biotech companies have tried and failed to treat cirrhosis:

Drugs target seere inflammation cannot rebuild lost tissue.
Devices and bioreactors provide only temporary support.
Transplants are scarce, costly, and require lifelong immunosuppression.
iPSC-hepatocyte and 3D-printed approaches fall short in restoring full liver mass or function.

Liver Cirrhosis results in a devastating human and financial toll: millions dying without options, billions spent on palliative care, and no scalable cure in sight.